Literature DB >> 25348731

Comparison of (18)F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer.

Corinna Altini1, Artor Niccoli Asabella, Raffaele De Luca, Margherita Fanelli, Cosimo Caliandro, Natale Quartuccio, Domenico Rubini, Angelina Cistaro, Severino Montemurro, Giuseppe Rubini.   

Abstract

PURPOSE: The aim of this study was to prospectively investigate the predictive value of (18)F-FDG PET/CT semiquantitative parameters for locally advanced low rectal cancer (LARC) treated by neoadjuvant chemoradiation therapy (nCRT).
METHODS: 68 patients with LARC had (18)F-FDG PET/CT scans twice (baseline and 5-6 weeks post-nCRT). All patients underwent surgery with preservation of the sphincter 8 weeks later. (18)F-FDG PET/CT analysis was performed by visual response assessment (VRA) and semiquantitative parameters: SUVmax(baseline), SUVmean(baseline), MTV(baseline), TLG(baseline), SUVmax(post-nCRT), SUVmean(post-nCRT), MTV(post-nCRT), TLG(post-nCRT); ΔSUVmax and mean and Response indexes (RImax% and RImean%). Assessment of nCRT tumor response was performed according to the Mandard's Tumor Regression Grade (TRG) and (y)pTNM staging on the surgical specimens. Concordances of VRA with TRG, and with (y)pTNM criteria were evaluated by Cohen's K. Results were compared by t student test for unpaired groups. ROC curve analysis was performed.
RESULTS: VRA analysis of post-nCRT (18)F-FDG PET/CT scan for the (y)pTNM outcome showed sensitivity, specificity, accuracy, PPV, and NPV of 87.5%, 66.7%, 83.8%, 92.5%, and 53.3%, respectively. Concordances of VRA with TRG and with (y)pTNM were moderate. For the outcome variable TRG, the statistical difference between responders and non-responders was significant for SUVmax(post-nCRT) and RImean%; for the outcome variable (y)pTNM, there was a significant difference for MTV(baseline), SUVmax(post-nCRT), SUVmean(post-nCRT), MTV(post-nCRT), RImax%, and RImean%. ROC analysis showed better AUCs: for the outcome variable TRG for SUVmax(post-nCRT), SUVmean(post-nCRT), and RImean%; for the outcome variable (y)pTNM for MTVbaseline, SUVmax(post-nCRT), SUVmean(post-nCRT), MTV(post-nCRT), RImax%, and RImean%. No significant differences among parameters were found.
CONCLUSIONS: Qualitative and semiquantitative evaluations for (18)F-FDG PET/CT are the optimal approach; a valid parameter for response prediction has still to be established.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25348731     DOI: 10.1007/s00261-014-0277-8

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  7 in total

1.  PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.

Authors:  Oke Gerke; Karen Ehlers; Edith Motschall; Poul Flemming Høilund-Carlsen; Werner Vach
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

Review 2.  The use of PET/MRI for imaging rectal cancer.

Authors:  Thomas A Hope; Zahra Kassam; Andreas Loening; Michelle M McNamara; Raj Paspulati
Journal:  Abdom Radiol (NY)       Date:  2019-11

3.  18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography.

Authors:  Corinna Altini; Artor Niccoli Asabella; Alessandra Di Palo; Margherita Fanelli; Cristina Ferrari; Marco Moschetta; Giuseppe Rubini
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

4.  Magnetic Resonance Imaging Evaluation in Neoadjuvant Therapy of Locally Advanced Rectal Cancer: A Systematic Review.

Authors:  Roberta Fusco; Mario Petrillo; Vincenza Granata; Salvatore Filice; Mario Sansone; Orlando Catalano; Antonella Petrillo
Journal:  Radiol Oncol       Date:  2017-08-16       Impact factor: 2.991

5.  Association of visual and quantitative heterogeneity of 18F-FDG PET images with treatment response in locally advanced rectal cancer: A feasibility study.

Authors:  Paula Martin-Gonzalez; Estibaliz Gomez de Mariscal; M Elena Martino; Pedro M Gordaliza; Isabel Peligros; Jose Luis Carreras; Felipe A Calvo; Javier Pascau; Manuel Desco; Arrate Muñoz-Barrutia
Journal:  PLoS One       Date:  2020-11-30       Impact factor: 3.240

Review 6.  Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.

Authors:  Thomas J George; Carmen J Allegra; Greg Yothers
Journal:  Curr Colorectal Cancer Rep       Date:  2015

Review 7.  Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.

Authors:  Girolamo Ranieri; Ilaria Marech; Artor Niccoli Asabella; Alessandra Di Palo; Mariangela Porcelli; Valentina Lavelli; Giuseppe Rubini; Cristina Ferrari; Cosmo Damiano Gadaleta
Journal:  Int J Mol Sci       Date:  2017-09-09       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.